Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024, reflecting a significant reduction in costs [17] - Revenues for 2025 totaled approximately $3.9 million, down from approximately $5.6 million in the previous year, primarily due to lower revenue from AgPlenus [22] - The net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the same period last year, indicating improved financial performance [31] Business Line Data and Key Metrics Changes - R&D expenses for 2025 were approximately $8 million, a decrease of approximately $4.5 million compared to 2024, mainly due to reduced expenses in Biomica, Casterra, and AgPlenus [24] - Sales and marketing expenses for 2025 were approximately $1.5 million, down from approximately $2 million in the previous year, reflecting cost-cutting measures [25] - AgPlenus continues to apply ChemPass AI for the development of novel herbicides and fungicides, with expectations for growth through collaborations with Bayer and Corteva [14] Market Data and Key Metrics Changes - Casterra Ag ceased operations in Kenya and is focusing on the Brazilian market, leading to an impairment of approximately $2.2 million related to seed inventory [19] - The agricultural market has seen a decline in demand, affecting Casterra's operations, but there is an expectation of increased collaboration opportunities as the need for innovation grows [41] Company Strategy and Development Direction - The company has shifted its focus to two high-impact markets: human health and agriculture, utilizing the ChemPass AI platform for drug development and ag chemicals [8] - The strategic transformation includes discontinuing non-core activities and resizing the organization to enhance operational efficiency [7] - The long-term goal is to develop a proprietary product pipeline while becoming the partner of choice for small molecule discovery and optimization [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of strategic partnerships and collaborations to enhance the company's capabilities and market position [12] - The company expects to maintain sufficient cash flow for operations for at least a year and a half, even without additional financial transactions [36] - Management anticipates significant future catalysts, including technology collaborations and partnerships with larger biotech and ag chemical companies [39][41] Other Important Information - The company recognized a gain on the sale of Lavie Bio's assets, amounting to approximately $6.4 million, which contributed to the income from discontinued operations [31] - As of December 31, 2025, the company held approximately $13 million in cash equivalents and short-term bank deposits [21] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on the advancement of BMC128 and revenue sharing from the end product [34] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year, with sufficient cash for over a year and a half [36] Question: What are the expected investor catalysts over the coming 12 months? - Anticipated catalysts include technology collaborations with companies like Google, additional agreements with biotech and pharma companies, and collaborations with ag chemical companies [39][41]

Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024, reflecting a significant reduction in costs [17] - Total operating expenses net for Q4 2025 were approximately $3.2 million, down from approximately $4.3 million in Q4 2024 [17] - Revenues for 2025 totaled approximately $3.9 million, a decrease from approximately $5.6 million in the previous year, primarily due to lower revenue from AgPlenus [22] - Net loss for 2025 was approximately $7.8 million, a decrease from approximately $18.1 million in the previous year, attributed to reduced operating expenses and income from discontinued operations [31] Business Line Data and Key Metrics Changes - AgPlenus, the agriculture subsidiary, continues to apply ChemPass AI for developing novel herbicides and fungicides, with expectations for growth through collaborations with Bayer and Corteva [14] - Casterra Ag ceased operations in Kenya and recorded an impairment of approximately $2.2 million related to seed inventory due to a decline in demand for castor seeds [19][23] - Biomica scaled down operations and entered into a license agreement with Lishan Pharmaceuticals for its lead oncology candidate, BMC128 [18] Market Data and Key Metrics Changes - The agriculture industry has faced negative performance in recent years, impacting collaboration appetites, but there is a growing need for innovation [41] - The company anticipates that cash from Lavie Bio and Biomica will satisfy operational needs for at least the next year and a half [36] Company Strategy and Development Direction - The company has focused its technology development on a single computational engine, ChemPass AI, and streamlined operations to concentrate on human health and agriculture [8] - The mission is to design novel small molecules optimized for drug development and agricultural chemicals, leveraging ChemPass AI's capabilities [7][15] - The company aims to become the partner of choice for small molecule discovery and optimization in both pharma and agriculture sectors [15] Management Comments on Operating Environment and Future Outlook - Management highlighted the strategic transformation to direct resources for sustainable value creation, emphasizing the competitive advantage of ChemPass AI [6][8] - The company expects to scale collaborations and partnerships, enhancing the likelihood of advancing proprietary candidate molecules [12][14] - Management expressed confidence in achieving targets and continuing to update stakeholders on progress [43] Other Important Information - The company recognized a gain on the sale of Lavie Bio's assets, contributing to income from discontinued operations [31] - Cash position as of December 31, 2025, was approximately $13 million, with cash usage during Q4 2025 at approximately $3 million [21][22] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on advancing BMC128 in the pipeline and revenue sharing from the end product [34] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year, with sufficient cash for over a year and a half [36] Question: What are the expected investor catalysts over the coming 12 months? - Three types of catalysts are anticipated: technology collaborations with companies like Google, additional collaborations with biotech and pharma companies, and collaborations with ag chemical companies [37][41]

Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024 [16] - Total operating expenses net for Q4 2025 were approximately $3.2 million, down from approximately $4.3 million in Q4 2024 [16] - Revenues for 2025 totaled approximately $3.9 million, a decrease from approximately $5.6 million in 2024 [21] - Net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the previous year [30] - Operating loss for Q4 2025 was approximately $5.2 million, an increase from approximately $3.5 million in Q4 2024 [26] Business Line Data and Key Metrics Changes - Lavie Bio Ltd. completed the sale of the majority of its operations, significantly reducing its operational expenses [17] - Biomica scaled down operations and entered into a license agreement with Lishan Pharmaceuticals for its lead oncology candidate [17] - AgPlenus integrated into core operations, focusing on novel ag chemical products [18] - Casterra Ag ceased operations in Kenya and recorded an impairment of approximately $2.2 million related to its seed inventory [18][22] Market Data and Key Metrics Changes - The demand for castor seeds significantly declined, impacting Casterra's operations [18] - The agriculture industry has faced negative performance, affecting collaboration willingness, but there are signs of improvement [40] Company Strategy and Development Direction - The company has focused on two high-impact markets: human health and agriculture, utilizing ChemPass AI for drug development and ag chemicals [8] - A strategic transformation was initiated to streamline operations and enhance long-term value creation [6] - The mission is to become the partner of choice for small molecule discovery and optimization in pharma and agriculture [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of reduced expense levels and the potential for cash inflow from Lavie Bio and Biomica [35] - The company anticipates significant future collaborations with technology and pharmaceutical companies, which could serve as catalysts for growth [36][40] Other Important Information - The company held consolidated cash equivalents of approximately $13 million as of December 31, 2025 [20] - Financing income net for 2025 was approximately $0.6 million, a decrease from approximately $4 million in the previous year [26] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on advancing BMC128 and revenue sharing from the end product [33] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year [35] Question: What are the expected investor catalysts over the coming 12 months? - Three types of catalysts were identified: technology collaborations, additional pharma collaborations, and ag chemical collaborations [36][40]

Core Insights - The partnership between Evogene Ltd. and Unravel Biosciences aims to address the unmet need for remyelination therapies in multiple sclerosis and other demyelinating conditions by leveraging advanced generative chemistry design and predictive platforms [1][2][3] Company Overview - Evogene Ltd. is a pioneering computational chemistry company specializing in the generative design of small molecules for pharmaceutical and agricultural industries [7] - Unravel Biosciences is a clinical-stage therapeutics company focused on advancing drugs for complex diseases through its Predictable Medicine platform [10] Collaboration Details - The collaboration seeks to design and validate brain-penetrant inhibitors targeting a novel demyelination target identified by Unravel's platform, aiming to create the first therapeutic capable of restoring myelin and improving neurological function [3][4] - Evogene's ChemPass AI will be utilized to advance novel drug targets for remyelination, optimizing drug candidates based on insights from Unravel's experimental systems [5][6] Scientific Approach - The partnership combines Evogene's state-of-the-art computational capabilities with Unravel's AI-powered predictive biology platform, utilizing RNA-based simulations and patient data to generate novel therapeutic insights [4][6] - The collaboration emphasizes a function-first discovery approach to gain biological insights from genetically defined demyelinating disorders, facilitating the translation of these insights into therapeutic applications [3][5] Market Need - Degenerative diseases, particularly demyelinating diseases like Multiple Sclerosis, affect hundreds of millions globally, with MS impacting approximately 3 million people [2] - Current therapies primarily focus on slowing disease progression rather than repairing existing damage, highlighting a significant unmet need for effective treatments that can reverse myelin loss [2]

Core Insights - Evogene Ltd. is focusing on computational chemistry and the generative design of small molecules for pharmaceuticals and agriculture, with a strategic emphasis on its AI-driven platform, ChemPass AI [1] Financial Performance - On November 20, 2025, Evogene reported earnings per share of $0.44, exceeding the estimated loss of $0.41 per share [2][5] - The company generated revenue of $312,000, which was below the estimated $650,000, indicating challenges in meeting market expectations [2][5] Valuation Metrics - The price-to-sales ratio is approximately 1.40, indicating that investors are willing to pay $1.40 for every dollar of sales, reflecting confidence in Evogene's potential [3] - The enterprise value to sales ratio stands at about 2.04, showing the company's valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is around -0.78, suggesting difficulties in generating positive cash flow from operations [3] Liquidity and Debt Position - Evogene's debt-to-equity ratio is approximately -3.57, indicating more liabilities than equity [4] - The current ratio is about 1.89, suggesting a relatively healthy liquidity position that allows the company to cover its short-term obligations [4]

Core Insights - Evogene Ltd. will release its financial results for Q3 2025 on November 20, 2025, followed by a conference call at 9:00 AM ET to discuss the results [1][2]. Company Overview - Evogene Ltd. is a pioneering company in computational chemistry, focusing on the generative design of small molecules for the pharmaceutical and agricultural sectors [3]. - The company's technology is centered around ChemPass AI, a proprietary generative AI engine that enhances the design of novel, highly potent small molecules, optimizing multiple critical parameters [3]. - This platform aims to improve success rates while reducing development time and costs [3]. Strategic Focus - Evogene is dedicated to creating breakthrough products through strategic partnerships and internal product development, emphasizing the integration of scientific innovation with real-world industry needs, termed "Real-World Innovation" [4].

Core Insights - Evogene Ltd. will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025 [1] - The presentation will focus on the strategic emphasis on ChemPass AI, a proprietary generative AI technology for small molecule discovery and optimization in pharmaceuticals and agriculture [2] - One-on-one meetings will be available for interested investors and companies during the conference [3] Company Overview - Evogene Ltd. is an AI-driven discovery and development company specializing in novel small molecules for the pharmaceutical and agricultural chemical industries [4] - The company's innovation is centered around ChemPass AI, designed to create highly potent small molecules while addressing challenges in discovery and optimization [4] - Evogene aims to enhance the probability of success and reduce development costs through its technology, which supports both strategic partnerships and internal product pipelines [4]

Core Insights - Evogene Ltd. is undergoing a transformative phase focused on its ChemPass AI platform for AI-driven discovery and optimization of small molecules, targeting the pharmaceutical and agricultural markets [3][11]. Financial Performance - For the first half of 2025, total revenues were approximately $3.2 million, up from $2.3 million in the same period of 2024, primarily due to increased seed sales from Casterra [8][15]. - Total operating expenses for the first half of 2025 were approximately $7.7 million, a decrease from $11.1 million in the first half of 2024, attributed to reduced activities in subsidiaries [8][20]. - The net loss for the first half of 2025 was approximately $7.7 million, compared to $9.8 million in the same period last year, reflecting decreased operating expenses and increased financing income [8][23]. Strategic Developments - The company launched version 1.0 of its generative AI foundation model in partnership with Google Cloud, trained on a dataset of approximately 38 billion molecular structures [5]. - A collaboration with Tel Aviv University was announced to discover small molecule therapeutics for metabolic diseases, marking the start of a broader pharmaceutical ecosystem [6]. - Evogene is integrating AgPlenus' activities into its operations, which includes a 40% workforce reduction at AgPlenus to enhance operational efficiency [7]. Cash Position and Financing - As of June 30, 2025, Evogene had a cash balance of approximately $11.7 million, with cash usage during the second quarter of 2025 at approximately $2.4 million [12]. - The company raised $4.4 million through its existing at-the-market facility in June 2025, reflecting strong market confidence [10]. Operational Focus - The company is streamlining operations and focusing on enhancing ChemPass AI as its core engine, expanding strategic collaborations in pharmaceuticals, and optimizing agricultural offerings [9][14]. - Evogene executed a 30% workforce reduction, with cost savings expected to be realized from the third quarter of 2025 onwards [13].

Core Insights - Evogene Ltd. has entered a scientific collaboration with Professor Ehud Gazit's research group from Tel Aviv University to develop novel small molecules aimed at inhibiting pathological self-assembly processes associated with diseases like Tyrosinemia and Gout [1][3][5] Company Overview - Evogene Ltd. is a computational biology and chemistry company that utilizes big data and artificial intelligence to enhance the development of life-science products, aiming to increase success rates while reducing time and costs [6][7] Collaboration Details - The partnership will leverage Evogene's ChemPass AI technology, which focuses on generative molecular design, combined with Professor Gazit's expertise in molecular self-assembly [4][5] - The collaboration aims to create therapeutics that specifically target the self-assembly of small metabolites, potentially benefiting millions of patients suffering from related diseases [3][5] Technological Capabilities - Evogene has developed three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different aspects of product development [7] - ChemPass AI will be utilized to drive generative molecular design, creating novel molecules tailored for therapeutic efficacy [7]

Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science product discovery and development through big data and artificial intelligence [3][4] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each targeting different core components for product development [4] Upcoming Financial Results - Evogene will release its financial results for the first quarter of 2025 on August 19, 2025 [1] - A conference call to discuss these results will be held at 9:00 AM Eastern Time on the same day [2] Strategic Partnerships and Subsidiaries - Evogene collaborates with various subsidiaries to develop products, including: - Biomica Ltd. focuses on microbiome-based therapeutics [5] - Lavie Bio Ltd. works on microbiome-based ag-biologicals [5] - AgPlenus Ltd. develops next-generation agricultural chemicals [5] - Casterra Ag Ltd. markets superior castor seed varieties for biofuel and other industries [5]